Hydrogels for hMSC delivery & engraftment

用于 hMSC 递送的水凝胶

基本信息

  • 批准号:
    8708495
  • 负责人:
  • 金额:
    $ 29.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mesenchymal stem cells (MSC) represent a promising cell source for regenerative medicine applications. Transplanted MSC enhance bone, cartilage, and intervertebral disc repair in pre-clinical models and initial clinical trials. Howevr, the engraftment of transplanted MSC is extremely low, and the beneficial effects are generally attributed to trophic/paracrine actions. The low engraftment and survival of transplanted MSC significantly limit these cell-based therapies in the repair of challenging, non-healing defects. A major hurdle to MSC survival and engraftment is the lack of appropriate bioactive delivery vehicles. The objective of this project is to engineer biofunctional hydrogels to direct human MSC (hMSC) survival, engraftment, and function. Our central hypothesis is that hydrogels presenting integrin-specific adhesive ligands will promote hMSC engraftment, osteogenesis, and bone repair. This work will establish bioactive cell delivery vehicles that enhance MSC survival, engraftment and function compared to existing synthetic matrices. Aim 1: Engineer hydrogels presenting integrin-specific adhesive ligands to direct hMSC fate commitment and differentiation. Aim 2: Evaluate the ability of integrin-specific hydrogels to promote hMSC survival, engraftment, and bone repair. Aim 3: Analyze the effects of VEGF co-delivery from hydrogels on hMSC engraftment and bone repair. The proposed research is innovative because it focuses on exploiting integrin binding specificity to control hMSC survival, engraftment and function for bone repair and integrates new in vivo imaging approaches. This work is expected to yield the following outcomes. First, we will determine the extent to which integrin-specific ligands regulate hMSC signaling, commitment and differentiation into osteogenic, adipogenic and chondrogenic lineages. We will also establish novel bioactive cell delivery vehicles that enhance MSC survival, engraftment and bone formation for improved bone repair. Finally, because of the transformative potential of MSC, this research will have broad significance and impact to many regenerative medicine applications.
描述(由申请人提供):间充质干细胞(MSC)代表了再生医学应用的有前途的细胞来源。移植的MSC在临床前模型和初始临床试验中增强骨、软骨和椎间盘修复。然而,移植的MSC的植入率极低,并且有益效果通常归因于营养/旁分泌作用。移植MSC的低植入和存活显著限制了这些基于细胞的疗法在修复具有挑战性的非愈合性缺陷中的应用。一 MSC存活和移植的主要障碍是缺乏合适的生物活性递送载体。该项目的目的是设计生物功能水凝胶来指导人类MSC(hMSC)的存活,植入和功能。我们的中心假设是,水凝胶呈现整合素特异性粘附配体将促进hMSC植入,骨生成和骨修复。这项工作将建立生物活性细胞递送载体,与现有的合成基质相比,增强MSC的存活、植入和功能。目的1:工程水凝胶呈现整合素特异性粘附配体,以指导hMSC命运定型和分化。目的2:评价整合素特异性水凝胶促进hMSC存活、植入和骨修复的能力。目的3:分析水凝胶共递送VEGF对hMSC植入和骨修复的影响。拟议的研究是创新的,因为它专注于利用整合素结合特异性来控制hMSC的生存,植入和骨修复功能,并整合了新的体内成像方法。这项工作预计将产生以下成果。首先,我们将确定整合素特异性配体在多大程度上调节hMSC信号传导、定向和分化成成骨、成脂和成软骨谱系。我们还将建立新的生物活性细胞载体,增强MSC的存活,植入和骨形成,以改善骨修复。最后,由于MSC的变革潜力,这项研究将对许多再生医学应用产生广泛的意义和影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andres J Garcia其他文献

Andres J Garcia的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andres J Garcia', 18)}}的其他基金

Hydrogels for human beta cell survival, function and evasion of immune rejection
用于人类β细胞存活、功能和逃避免疫排斥的水凝胶
  • 批准号:
    10512947
  • 财政年份:
    2022
  • 资助金额:
    $ 29.69万
  • 项目类别:
Hydrogels for human beta cell survival, function and evasion of immune rejection
用于人类β细胞存活、功能和逃避免疫排斥的水凝胶
  • 批准号:
    10705265
  • 财政年份:
    2022
  • 资助金额:
    $ 29.69万
  • 项目类别:
Hydrogels for human beta cell survival, function and evasion of immune rejection
用于人类β细胞存活、功能和逃避免疫排斥的水凝胶
  • 批准号:
    10865870
  • 财政年份:
    2022
  • 资助金额:
    $ 29.69万
  • 项目类别:
BIOMATERIALS FOR STEM CELL DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
  • 批准号:
    10517827
  • 财政年份:
    2021
  • 资助金额:
    $ 29.69万
  • 项目类别:
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
  • 批准号:
    10684716
  • 财政年份:
    2021
  • 资助金额:
    $ 29.69万
  • 项目类别:
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
  • 批准号:
    10306891
  • 财政年份:
    2021
  • 资助金额:
    $ 29.69万
  • 项目类别:
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
  • 批准号:
    10557968
  • 财政年份:
    2021
  • 资助金额:
    $ 29.69万
  • 项目类别:
BIOMATERIALS FOR STEM CELL-DERIVED BETA CELL TRANSPLANTATION
用于干细胞衍生的 β 细胞移植的生物材料
  • 批准号:
    10905940
  • 财政年份:
    2021
  • 资助金额:
    $ 29.69万
  • 项目类别:
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts
靶向递送免疫调节生物制剂以诱导同种异体胰岛移植物的免疫特权
  • 批准号:
    10227259
  • 财政年份:
    2020
  • 资助金额:
    $ 29.69万
  • 项目类别:
Hydrogels for delivery of muscle stem cells to diaphragm
用于将肌肉干细胞递送至隔膜的水凝胶
  • 批准号:
    10281444
  • 财政年份:
    2020
  • 资助金额:
    $ 29.69万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 29.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了